Eyal Rubin M.B.A. Net Worth

Mr. Eyal Rubin M.B.A. biography

Eyal Rubin M.B.A. is the Sr. VP, CFO, Treasurer & Corp. Sec. at Protalix BioTherapeutics.

What is the salary of Mr A?

As the Sr. VP, CFO e Treasurer & Corp. Sec. of Protalix BioTherapeutics, the total compensation of Mr A at Protalix BioTherapeutics is $494,885. There are 3 executives at Protalix BioTherapeutics getting paid more, with Dr. Einat Brill-Almon having the highest compensation of $665,703.

How old is Mr A?

Mr A is 45, he's been the Sr. VP, CFO e Treasurer & Corp. Sec. of Protalix BioTherapeutics since . There are 11 older and 2 younger executives at Protalix BioTherapeutics. The oldest executive at Protalix BioTherapeutics Inc. is Aharon Schwartz, 75, who is the Independent Director.

What's Mr A's mailing address?

Eyal's mailing address filed with the SEC is C/O PROTALIX BIOTHERAPEUTICS, INC., 2 SNUNIT STREET SCIENCE PARK, POB 455, CARMIEL, L3, 2161401.

Insiders trading at Protalix BioTherapeutics

Over the last 18 years, insiders at Protalix BioTherapeutics have traded over $46,705,936 worth of Protalix BioTherapeutics stock and bought 4,403,619 units worth $4,673,005 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Capital Management Lp Camber e Ltd Bio Cell. On average, Protalix BioTherapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $404,231. The most recent stock trade was executed by Dror Bashan on 19 October 2023, trading 64,516 units of PLX stock currently worth $90,322.

What does Protalix BioTherapeutics do?

protalix is a publicly traded, clinical stage biopharmaceutical company (nyse, tase: plx) focused on the development and commercialization of recombinant therapeutic proteins using its proprietary procellex™ plant cell culture protein expression system. procellex provides a unique platform on which we have established a pipeline of proprietary and biosimilar versions of recombinant therapeutic proteins, relying upon known biological mechanisms of action. protalix's lead product, taliglucerase-alfa is an enzyme replacement therapy for the treatment of gaucher´s disease. protalix has concluded phase iii studies for this drug and is currently undergoing fda review. treatment is currently being provided by protalix to gaucher patients under clinical studies and companionate programs to hundreds of patients worldwide. this product has been licensed to pfizer. protalix's pipeline includes multiple therapeutic protein candidates including: acetylcholinesterase (biodefense); alfa‐galactosidase

Protalix BioTherapeutics executives and stock owners

Protalix BioTherapeutics executives and other stock owners filed with the SEC include:

• Dr. Einat Brill-Almon,
  Sr. VP & Chief Devel. Officer
• Dror Bashan,
  Pres, CEO & Director
• Einat Almon,
  Senior Vice President, Chief Development Officer
• Eyal Rubin M.B.A.,
  Sr. VP, CFO, Treasurer & Corp. Sec.
• Marcy Nanus,
  Investor Contact
• Aharon Schwartz,
  Independent Director
• David Granot,
  Independent Director
• Amos Bar-Shalev,
  Independent Director
• Gwen Melincoff,
  Director
• Pol Boudes,
  Director
• Yael Hayon,
  Vice President - Research & Development
• Yaron Naos,
  Senior Vice President - Operations
• Eyal Rubin,
  Chief Financial Officer, Senior Vice President
• Dror Bashan,
  President, Chief Executive Officer, Director
• Zeev Bronfeld,
  Chairman of the Board
• Dafna Shelly M.Sc., MBA,
  VP of HR
• Yaron Naos,
  Sr. VP of Operations
• Capital Management Lp Camber,
  10% owner
• Yoseph Shaaltiel,
  Executive VP, R&D
• Tzvi Palash,
  Chief Operating Officer
• Moshe Manor,
  President & CEO
• Yossi Maimon,
  VP, Chief Financial Officer
• Sandra Leigh Lauterbach,
  VP, Sales & Commercial Affairs
• David Aviezer,
  President & CEO
• Ltd Bio Cell,
  10% owner
• Shlomo Yanai,
  Director
• Alfred Akirov,
  Director
• Eli Hurvitz,
  Director
• Roger D. Kornberg,
  Director
• Phillip Md Et Al Frost Gamm...,
  
• Iftah Katz,
  VP of Operations
• Pharma Technologies Ltd.Ore...,
  
• Eliot Forster,
  Director
• Zvi Shmuel Ben,